Business Description
Monte Rosa Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US61225M1027
Description
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, they employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their most advanced product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.05 | |||||
| Equity-to-Asset | 0.59 | |||||
| Debt-to-Equity | 0.26 | |||||
| Debt-to-EBITDA | -0.34 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -28.3 | |||||
| 3-Year EPS without NRI Growth Rate | -16.7 | |||||
| 3-Year FCF Growth Rate | -0.2 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 15.2 | |||||
| 9-Day RSI | 26.53 | |||||
| 14-Day RSI | 34.97 | |||||
| 6-1 Month Momentum % | 163.6 | |||||
| 12-1 Month Momentum % | 43.26 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.07 | |||||
| Quick Ratio | 5.07 | |||||
| Cash Ratio | 4.99 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.6 | |||||
| Shareholder Yield % | -3.48 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -61.94 | |||||
| ROA % | -45.55 | |||||
| ROIC % | -172.05 | |||||
| ROC (Joel Greenblatt) % | -225.04 | |||||
| ROCE % | -53.02 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.49 | |||||
| Price-to-Tangible-Book | 1.49 | |||||
| EV-to-EBIT | -0.56 | |||||
| EV-to-Forward-EBIT | -0.55 | |||||
| EV-to-EBITDA | -0.59 | |||||
| EV-to-Forward-EBITDA | -0.56 | |||||
| EV-to-Forward-Revenue | 5.4 | |||||
| EV-to-FCF | -1.29 | |||||
| Price-to-Net-Current-Asset-Value | 2.39 | |||||
| Price-to-Net-Cash | 2.48 | |||||
| Earnings Yield (Greenblatt) % | -178.57 | |||||
| FCF Yield % | -23.51 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:GLUE
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Monte Rosa Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.63 | ||
| Beta | 0 | ||
| Volatility % | 125.19 | ||
| 14-Day RSI | 34.97 | ||
| 14-Day ATR ($) | 0.528077 | ||
| 20-Day SMA ($) | 6.469 | ||
| 12-1 Month Momentum % | 43.26 | ||
| 52-Week Range ($) | 2.44 - 8.84 | ||
| Shares Outstanding (Mil) | 50.15 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Monte Rosa Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Monte Rosa Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Monte Rosa Therapeutics Inc Frequently Asked Questions
What is Monte Rosa Therapeutics Inc(GLUE)'s stock price today?
The current price of GLUE is $5.33. The 52 week high of GLUE is $8.84 and 52 week low is $2.44.
When is next earnings date of Monte Rosa Therapeutics Inc(GLUE)?
The next earnings date of Monte Rosa Therapeutics Inc(GLUE) is 2024-05-10 Est..
Does Monte Rosa Therapeutics Inc(GLUE) pay dividends? If so, how much?
Monte Rosa Therapeutics Inc(GLUE) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers